Literature DB >> 27879033

Regulation of the placental BCRP transporter by PPAR gamma.

Yixin Lin1, Kristin M Bircsak1, Ludwik Gorczyca1, Xia Wen1, Lauren M Aleksunes1,2.   

Abstract

Identifying regulators of placental breast cancer resistance protein (BCRP) expression is critical as downregulation of this transporter may increase exposure of the fetus to xenobiotics. Here, we sought to test whether the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) regulates BCRP expression in the placenta. To test this, human BeWo placental choriocarcinoma cells were cultured with the PPARγ agonist rosiglitazone or the PPARγ antagonist T0070907 for 24 h. Messenger RNA (mRNA) expression of syncytialization markers, GCM1 and hCGβ, as well as BCRP increased with PPARγ agonist treatment. Conversely, BCRP mRNA and protein expression decreased 30%-50% with PPARγ antagonist treatment. Rosiglitazone enhanced BCRP protein expression and transport activity, resulting in a 20% greater efflux of the substrate Hoechst 33342 compared with control cells. These results suggest that PPARγ can upregulate BCRP expression in the placenta, which may be important in understanding mechanisms that protect the fetus from xenobiotic exposure during development.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  ABCG2; BCRP; PPAR gamma; placenta; trophoblast

Mesh:

Substances:

Year:  2016        PMID: 27879033      PMCID: PMC5429197          DOI: 10.1002/jbt.21880

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  48 in total

1.  Regulator of G protein signaling 5 is a determinant of gestational hypertension and preeclampsia.

Authors:  Vasyl Holobotovskyy; Yee Seng Chong; Jennifer Burchell; Bo He; Michael Phillips; Leo Leader; Timothy V Murphy; Shaun L Sandow; Douglas J McKitrick; Adrian K Charles; Marianne Tare; Leonard F Arnolda; Ruth Ganss
Journal:  Sci Transl Med       Date:  2015-06-03       Impact factor: 17.956

2.  In Vitro Screening of Environmental Chemicals Identifies Zearalenone as a Novel Substrate of the Placental BCRP/ABCG2 Transporter.

Authors:  Jingcheng Xiao; Qi Wang; Kristin M Bircsak; Xia Wen; Lauren M Aleksunes
Journal:  Toxicol Res (Camb)       Date:  2015-05-01       Impact factor: 3.524

3.  Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.

Authors:  Antonius E van Herwaarden; Els Wagenaar; Barbara Karnekamp; Gracia Merino; Johan W Jonker; Alfred H Schinkel
Journal:  Carcinogenesis       Date:  2005-07-06       Impact factor: 4.944

4.  The hormone-synthesizing trophoblastic cell in vitro: a model for cancer research and placental hormone synthesis.

Authors:  R A Pattillo; G O Gey; E Delfs; W Y Huang; L Hause; D J Garancis; M Knoth; J Amatruda; J Bertino; H G Friesen; R F Mattingly
Journal:  Ann N Y Acad Sci       Date:  1971-01-28       Impact factor: 5.691

5.  The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study.

Authors:  Lin Zhou; Suresh Babu Naraharisetti; Honggang Wang; Jashvant D Unadkat; Mary F Hebert; Qingcheng Mao
Journal:  Mol Pharmacol       Date:  2007-12-13       Impact factor: 4.436

6.  The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction.

Authors:  Denis A Evseenko; Padma Murthi; James W Paxton; Glen Reid; B Starling Emerald; K M Mohankumar; Peter E Lobie; Shaun P Brennecke; Bill Kalionis; J A Keelan
Journal:  FASEB J       Date:  2007-06-26       Impact factor: 5.191

7.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

Authors:  R Allikmets; L M Schriml; A Hutchinson; V Romano-Spica; M Dean
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

8.  Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens.

Authors:  Junichi Enokizono; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Mol Pharmacol       Date:  2007-07-20       Impact factor: 4.436

9.  Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells.

Authors:  Honggang Wang; Eun-Woo Lee; Lin Zhou; Peter C K Leung; Douglas D Ross; Jashvant D Unadkat; Qingcheng Mao
Journal:  Mol Pharmacol       Date:  2007-11-27       Impact factor: 4.436

Review 10.  Pre-eclampsia: pathophysiology, diagnosis, and management.

Authors:  Jennifer Uzan; Marie Carbonnel; Olivier Piconne; Roland Asmar; Jean-Marc Ayoubi
Journal:  Vasc Health Risk Manag       Date:  2011-07-19
View more
  5 in total

Review 1.  Transcription factor-mediated regulation of the BCRP/ABCG2 efflux transporter: a review across tissues and species.

Authors:  Ludwik Gorczyca; Lauren M Aleksunes
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-03-14       Impact factor: 4.481

Review 2.  An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.

Authors:  Lyrialle W Han; Chunying Gao; Qingcheng Mao
Journal:  Expert Opin Drug Metab Toxicol       Date:  2018-08-03       Impact factor: 4.481

Review 3.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

4.  Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition.

Authors:  Dahea You; Jason R Richardson; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2020-03-19       Impact factor: 3.922

5.  Low oxygen tension differentially regulates the expression of placental solute carriers and ABC transporters.

Authors:  Ludwik Gorczyca; Jianyao Du; Kristin M Bircsak; Xia Wen; Anna M Vetrano; Lauren M Aleksunes
Journal:  FEBS Lett       Date:  2020-10-07       Impact factor: 4.124

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.